Disciplina de Infectologia, Laboratório de Virologia Clínica, Departamento de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
Laboratório Central, Hospital São Paulo, São Paulo, SP, Brasil.
Mem Inst Oswaldo Cruz. 2020;115:e200009. doi: 10.1590/0074-02760200009. Epub 2020 May 18.
BACKGROUND Influenza viral load (VL) can be a decisive factor in determining the antiviral efficacy in viral clearance. OBJECTIVE This study aimed to evaluate the rate of infection and the role of influenza VL on the clinical spectrum of illnesses among different patient groups attended at a tertiary hospital in Brazil. METHODS Samples were collected from patients presenting acute respiratory infection from 2009 to 2013. Overall, 2262 samples were analysed and distributed into three groups: (i) asymptomatic (AS); (ii) symptomatic outpatients (OP); and (iii) hospitalised patients (HP). VL (expressed in Log10 RNA copies/mL) was calculated through a quantitative real-time one-step reverse transcription-polymerase chain reaction (RT-PCR) assay aimed at the M gene, with human RNAseP target as internal control and normalising gene of threshold cycle values. FINDINGS A total of 162 (7.16%) H1N1pdm09 positive samples were analysed. Patients aged from 0.08 to 77 years old [median ± standard deviation (SD): 12.5 ± 20.54]. Children with 5 to 11 years old presented the highest detection (p < 0.0001). AS patients had the lowest VL, with a significant difference when compared with symptomatic patients (p = 0.0003). A higher VL was observed within two days of disease onset. Ten patients (HP group) received antiviral treatment and were followed up and presented a mean initial VL of 6.64 ± 1.82. A complete viral clearance for 50% of these patients was reached after 12 days of treatment. MAIN CONCLUSIONS It is important to evaluate AS patients as potential spreaders, as viral shedding was still present, even at lower VL. Our results suggest that patients with underlying diseases and severe clinical symptoms may be considered for prolonged viral treatment.
流感病毒载量(VL)可能是决定病毒清除率的抗病毒疗效的决定性因素。
本研究旨在评估巴西一家三级医院不同患者群体的感染率和流感 VL 在疾病临床谱中的作用。
从 2009 年至 2013 年出现急性呼吸道感染的患者中采集样本。总共分析了 2262 个样本,并分为三组:(i)无症状(AS);(ii)有症状的门诊患者(OP);和(iii)住院患者(HP)。通过实时一步定量 RT-PCR 检测计算 VL(以 Log10 RNA 拷贝/ml 表示),该检测针对 M 基因,以人 RNAseP 靶标作为内部对照,并对阈值循环值进行归一化基因。
共分析了 162 例(7.16%)H1N1pdm09 阳性样本。患者年龄从 0.08 至 77 岁[中位数±标准偏差(SD):12.5±20.54]。5 至 11 岁的儿童检测率最高(p<0.0001)。AS 患者的 VL 最低,与有症状患者相比差异有统计学意义(p=0.0003)。疾病发病后两天内观察到更高的 VL。10 例(HP 组)接受抗病毒治疗并进行随访,初始 VL 平均为 6.64±1.82。这些患者中有 50%的人在治疗 12 天后完全清除了病毒。
评估 AS 患者作为潜在的传播者很重要,因为即使 VL 较低,仍存在病毒脱落。我们的结果表明,患有基础疾病和严重临床症状的患者可能需要延长病毒治疗时间。